China Meheco First-Half 2026 Revenue RMB16.952 Billion, Net Profit RMB249 Million, Down 0.73% and 15.26% YoY
China Meheco reported first-half 2026 revenue of RMB16.952 billion, down 0.73% year on year, and net profit attributable to shareholders of RMB249 million, down 15.26%. Basic earnings per share stood at RMB0.1665. The company cited intensifying industry competition, deeper centralized procurement and medical insurance cost-control policies, and product price pressure as factors behind the decline.
China Meheco disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating revenue of RMB16.952 billion, a year-on-year decrease of 0.73%; net profit attributable to shareholders of the listed company was RMB249 million, a year-on-year decrease of 15.26%; basic earnings per share was RMB0.1665.
The company stated that the decline in performance was mainly due to factors including intensifying industry competition, the continued deepening of centralized procurement and medical insurance cost-control policies, and downward pressure on product prices.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is negative for Pharmaceuticals, with intensity 40/100 and 70% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.